WX-132-18B

WX-132-18B (72 h) potently inhibits the proliferation of HepG2, HeLa, A549, H460, BGC-823, MX-1, taxol-resistant MX-1/T, and HUVEC cells with IC₅₀ values ranging from 0.45 to 0.99 nM^[1].
WX-132-18B (1-10 nM; 24 h) reduces tubulin content and altering tubulin morphology with EC₅₀ values ranging from 2.99 to 9.43 nM^[1].
WX-132-18B (0.1-10 μM; 45 min pre-incubation with tubulin, 45 min incubation with colchicine) competitively binds to the colchicine-binding site on tubulin with an IC₅₀ of 0.47 μM^[1].
WX-132-18B (1-10 nM; 24-48 h) potently arrests A549 cells at the G2/M phase of the cell cycle within 24 h, induces concentration-dependent apoptosis in A549 cells after 48 h, and triggers concentration-dependent cytotoxicity in HepG2 cells at 24 h by increasing nuclear membrane permeability while reducing manganese superoxide dismutase levels and mitochondrial membrane potential^[1].
WX-132-18B (0.03-3 μM; per manufacturer instructions) exhibits high target selectivity, with no significant effect on 21 screened tumor-related signaling pathways and only weak, non-specific DNA damage (Rad51 foci induction) at high concentrations^[1].
WX-132-18B (compound 2) displays broad-spectrum and ultra-potent antiproliferative activity with low-to-subnanomolar GI₅₀ values across most NCI-60 human tumor cell lines, although its potency is decreased in HOP-92, MALME-3M, SK-MEL-28, UACC-257, OVCAR-5, and TK-10 cells. It also strongly inhibits the growth of A549, KB, and KB-VIN cells with GI₅₀ values of 2.20-3.20 nM^[2].
WX-132-18B (15 min preincubation; 20 min incubation with GTP) inhibits purified tubulin polymerization with an IC₅₀ of 0.77 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.